HEALTH OF WOMAN. 2020.4(150): 80–84; doi 10.15574/HW.2020.150.80
Lyalkin S. A., Syvak L. A., Verevkina N. O.
National Cancer Institute, Kyiv

The objective: was to determine the impact of androgen receptor (AR) expression on the effectiveness of the first and second line chemotherapy in patients with metastatic triple negative breast cancer (mTNBC).
Materials and methods. The impact of AR expression on treatment results was evaluated in patients with mTNBC received the first (n=122) and second (n=87) line chemotherapy in open randomized studies. The status of AR was evaluated by immunohistochemistry, AR positive patients were defined as having AR more than 10%.
Results. From 116 patients with mTBNC 44 (38%) were AR positive, 72 (62%) – AR negative. Median progression free survival in patients received the first line chemotherapy was 8 months in AR positive and 6 months in AR negative, p=0.27. The incidence of objective tumor response in mTNBC patients received the second line chemotherapy was 71.1% in AR negative and 76.92% in AR positive, p=0.48. Median progression free survival in patients received the second line chemotherapy was 6 months in AR positive and 4 months in AR negative, p=0.0045. Median overall survival in AR positive patients was statistically significantly higher (12 months versus 9 months, р=0.04).
Conclusions. Impact of AR expression on progression free and overall survival was proved for mTNBC patients received the second line chemotherapy.
Keywords: metastatic triple negative breast cancer, androgen receptor, chemotherapy, progression free survival, overall survival.

REFERENCES

1. Anders CK, Abramson V, Tan T, Dent R. 2016. The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics. Am Soc Clin Oncol Educ Book. 35:34-42. https://doi.org/10.1200/EDBK_159135; PMid:27249684

2. Arora А, Chaturvedi R et al. 2019. Expression of Androgen Receptor in Triple Negative Breast Cancer Biopsies and Its Correlation with Prognostic Markers. Indian Journal of Pathology: Research and Practice 8(2):1951-8. https://doi.org/10.21088/ijprp.2278.148X.8219.3

3. Bozovic Spasojevic I, Zardavas D, Brohee S et al. 2017. The prognostic role of androgen receptor in patients with early-stage breast cancer: a meta-analysis of clinical and gene expression data. Clin. Cancer Res. 23:2702-2712. https://doi.org/10.1158/1078-0432.CCR-16-0979; PMid:28151718

4. Claire H, Karandza V, Aktan G. 2019. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple negative breast cancer: a systematic literature review. Breast cancer research 21:143-157. https://doi.org/10.1186/s13058-019-1210-4; PMid:31842957 PMCid:PMC6916124

5. Choi JE, Kang SH, Lee SJ, Bae YK. 2015. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer. Ann Surg Oncol. 22(1):82-9. https://doi.org/10.1245/s10434-014-3984-z; PMid:25145503

6. Dana A, Franzese E, Centonze S et al. 2018. Triple-negative breast cancers: systematic review of the literature on molecular and clinical features with a focus on treatment with innovative drugs. Curr. Oncol. Rep. 20(10):76. https://doi.org/10.1007/s11912-018-0726-6; PMid:30128845

7. Forman D, Ferlay J. 2014. The global and regional burden of cancer. In: Stewart BW, Wild CP, editors, World Cancer Report 2014. International Agency for Research on Cancer, Lyon, France: 64185.

8. Gerratana L, Basile D, Buono G et al. 2018. Androgen receptor in triple negative breast cancer: a potential target for the targetless subtype. Cancer Treat Rev. 68:102-110. https://doi.org/10.1016/j.ctrv.2018.06.005; PMid:29940524

9. Giovannelli P, Di Donato M, Galasso G et al. 2018. The androgen receptor in breast cancer. Front. Endocrinol. 9:492. https://doi.org/10.3389/fendo.2018.00492; PMid:30210453 PMCid:PMC6122126

10. Perou CM. 2000. Molecular portraits of human breast tumors. Nature 406:747-752. https://doi.org/10.1038/35021093; PMid:10963602

11. Wang C, Pan B, Zhu H, Zhou Y, Mao F, Lin Y et al. 2016. Prognostic value of androgen receptor in triple negative breast cancer: a meta-analysis. Oncotarget. 7:46482-91. https://doi.org/10.18632/oncotarget.10208; PMid:27374089 PMCid:PMC5216811